Obesity and thyroid gland
Authors:
Petr Sucharda
Authors place of work:
3. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in the journal:
Čas. Lék. čes. 2022; 161: 194-197
Category:
Review Article
Summary
Decreased thyroid function (both overt and subclinical) is more frequent in overweight and obese people but hypothyroidism as cause of obesity is rare. Borderline or slightly elevated values of thyrotropin without other signs of autoimmune inflammation (elevated antibodies, changes at ultrasonography) are mostly consequence of hormonal/cytokine reactions to obesity, especially to hyperleptinemia. However, they simultaneously represent metabolic and cardiovascular risk factor.
Keywords:
obesity – leptin – thyroid gland – Adipokines – Hypothyroidism
Zdroje
- Charvát J. Hospodárné léčení poruch výměny látkové a chorob endokrinních. Praktický lékař 1927; 7: 347–354.
- Svačina Š. Vztah štítné žlázy k obezitě. In: Límanová Z (ed.). Štítná žláza. Trendy soudobé endokrinologie, sv. 2. Galén, Praha, 2006: 233–243.
- Doberský P, Doleček R, Šonka J. Léčení otylosti. SZN, Praha, 1967.
- Krotkiewski M. Thyroid hormones in the pathogenesis and treatment of obesity. Eur J Pharmacol 2002; 440: 85–98.
- De Geronimo V, Cannarella R, La Vignera S. Thyroid function and obesity: From mechanisms to the benefits of levothyroxine in obese patients. Endocr Metab Immune Disord Drug Targets 2021; 21: 1954–1960.
- Zhao M, Xie H, Shan H et al. Development of thyroid hormones and synthetic thyromimetics in non-alcoholic fatty liver disease. Int J Mol Sci 2022; 23: 1102.
- Sjouke B, Langslet G, Češka R et al. Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes Endocrinol 2014; 2: 455–463.
- Walczak K, Sieminska L. Obesity and thyroid axis. Int J Environ Res Public Health 2021; 18: 9434.
- Amin A, Dhillo WS, Murphy KG. The central effects of thyroid hormones on appetite. J Thyroid Res 2011; 2011: 306510.
- Senese R, Cioffi F, de Lange P et al. Thyroid: biological actions of 'nonclassical' thyroid hormones. J Endocrinol 2014; 221: R1–R12.
- Laurberg P, Knudsen N, Andersen S et al. Thyroid function and obesity. Eur Thyroid J 2012; 1: 159–167.
- Thuzar M, Ho KK. Brown adipose tissue in humans: regulation and metabolic significance. Eur J Endocrinol 2016; 175: 11–25.
- al-Adsani H, Hoffer LJ, Silva JE. Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab 1997; 82: 1118–1125.
- Fontenelle LC, Feitosa MM, Severo JS et al. Thyroid function in human obesity: underlying mechanisms. Horm Metab Res 2016; 48: 787–794.
- Ren R, Jiang X, Zhang X et al. Association between thyroid hormones and body fat in euthyroid subjects. Clin Endocrinol (Oxf) 2014; 80: 585–590.
- Bétry C, Challan-Belval MA, Bernard A et al. Increased TSH in obesity: Evidence for a BMI-independent association with leptin. Diabetes Metab 2015; 41: 248–251.
- Fekete C, Lechan RM. Central regulation of hypothalamic-pituitary-thyroid axis under physiological and pathophysiological conditions. Endocr Rev 2014; 35: 159–194.
- Lozanov LB, Gorcheva D, Lozanov BS et al. role of thyroid deficiency on adiponectin, leptin, and metabolic status in visceral obesity: a cross-sectional study. Horm Metab Res 2017; 49: 667–672.
- Límanová Z. Syndrom hypofunkce štítné žlázy. In: Límanová Z (ed.). Štítná žláza. Trendy soudobé endokrinologie, sv. 2. Galén, Praha, 2006: 151–163.
- Jiskra J. Záněty štítné žlázy. In: Límanová Z (ed.). Štítná žláza. Trendy soudobé endokrinologie, sv. 2. Galén, Praha, 2006: 165–177.
- Kunešová M, Müllerová D, Hainer V. Epidemiologie a zdravotní rizika obezity. In: Hainer V. a kol. Základy klinické obezitologie. Grada, Praha, 2021: 19–43.
- Song RH, Wang B, Yao QM et al. The impact of obesity on thyroid autoimmunity and dysfunction: a systematic review and meta-analysis. Front Immunol 2019; 10: 2349.
- van Hulsteijn LT, Pasquali R, Casanueva F et al. Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis. Eur J Endocrinol 2020; 182: 11–21.
- Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab 2014; 99: 923–931.
- Svačina Š, Fried M, Býma S, Matoulek M. Obezita. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Společnost všeobecného lékařství ČLS JEP, Praha, 2018.
- Pasquali R, Casanueva F, Haluzík M et al. European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity. Eur J Endocrinol 2020; 182: G1–G32.
- Knudsen N, Laurberg P, Rasmussen LB et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2005; 90: 4019–4024.
- Santini F, Marzullo P, Rotondi M et al. Mechanisms in endocrinology: the crosstalk between thyroid gland and adipose tissue: signal integration in health and disease. Eur J Endocrinol 2014; 171: R137–R152.
- Guan B, Chen Y, Yang J et al. Effect of bariatric surgery on thyroid function in obese patients: a systematic review and meta-analysis. Obes Surg 2017; 27: 3292–3305.
- Juiz-Valiña P, Outeiriño-Blanco E, Pértega S et al. Effect of weight loss after bariatric surgery on thyroid-stimulating hormone levels in euthyroid patients with morbid obesity. Nutrients 2019; 11: 1121.
- Licenziati MR, Valerio G, Vetrani I et al. Altered thyroid function and structure in children and adolescents who are overweight and obese: reversal after weight loss. J Clin Endocrinol Metab 2019; 104: 2757–2765.
- Lai Y, Wang J, Jiang F et al. The relationship between serum thyrotropin and components of metabolic syndrome. Endocr J 2011; 58: 23–30.
- Zhao M, Tang X, Yang T et al. Lipotoxicity, a potential risk factor for the increasing prevalence of subclinical hypothyroidism? J Clin Endocrinol Metab 2015; 100: 1887–1894.
- Chang YC, Hua SC, Chang CH et al. High TSH level within normal range is associated with obesity, dyslipidemia, hypertension, inflammation, hypercoagulability, and the metabolic syndrome: A novel cardiometabolic marker. J Clin Med 2019; 8: 817.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Metamizole vs. Tramadol in Postoperative Analgesia
- Spasmolytic Effect of Metamizole
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- Hippocratic Oath and current medical oaths
- Management of Graves’ ophthalmopathy – 2022 update
- 125 let od narození profesora Josefa Charváta
- The importance of molecular autopsy in forensic medicine